By Steve Usdin
Contributing Editor

WASHINGTON - In its campaign to expand pediatric drug development, FDA will give precedence to incentives for sponsors to conduct pediatric trials on a voluntary basis rather than focus on the agency's regulatory authority to demand such studies, according to Diane Murphy, associate director of pediatrics at FDA's Center for Drug Evaluation and Research (CDER).